EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment

Prabhanjan Giram iD, Kazi Md Mahabubur Rahman, Osama Aqel, Youngjae You iD

ACS Biomaterials Science & Engineering · 12.05.2025 · 11 (5) · 2550-2583

DOI: 10.1021/acsbiomaterials.5c00121 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Biomaterials Science & Engineering, online erschienen am 14.04.2025. Verfasst von Prabhanjan Giram und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214, United States. Hauptthemen laut MEDLINE: Cancer Vaccines, Tumor Microenvironment, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is one of the leading causes of mortality worldwide. Nanomedicines have significantly improved life expectancy and survival rates for cancer patients in current standard care. However, recurrence of cancer due to metastasis remains a significant challenge. Vaccines can provide long-term protection and are ideal for preventing bacterial and viral infections. Cancer vaccines, however, have shown limited therapeutic efficacy and raised safety concerns despite extensive research. Cancer vaccines target and stimulate responses against tumor-specific antigens and have demonstrated great potential for cancer treatment in preclinical studies. However, tumor-associated immunosuppression and immune tolerance driven by immunoediting pose significant challenges for vaccine design. In situ vaccination represents an alternative approach to traditional cancer vaccines. This strategy involves the intratumoral administration of immunostimulants to modulate the growth and differentiation of innate immune cells, such as dendritic cells, macrophages, and neutrophils, and restore T-cell activity. Currently approved in situ vaccines, such as T-VEC, have demonstrated clinical promise, while ongoing clinical trials continue to explore novel strategies for broader efficacy. Despite these advancements, failures in vaccine research highlight the need to address tumor-associated immune suppression and immune escape mechanisms. In situ vaccination strategies combine innate and adaptive immune stimulation, leveraging tumor-associated antigens to activate dendritic cells and cross-prime CD8+ T cells. Various vaccine modalities, such as nucleotide-based vaccines (e.g., RNA and DNA vaccines), peptide-based vaccines, and cell-based vaccines (including dendritic, T-cell, and B-cell approaches), show significant potential. Plant-based viral approaches, including cowpea mosaic virus and Newcastle disease virus, further expand the toolkit for in situ vaccination. Therapeutic modalities such as chemotherapy, radiation, photodynamic therapy, photothermal therapy, and Checkpoint blockade inhibitors contribute to enhanced antigen presentation and immune activation. Adjuvants like CpG-ODN and PRR agonists further enhance immune modulation and vaccine efficacy. The advantages of in situ vaccination include patient specificity, personalization, minimized antigen immune escape, and reduced logistical costs. However, significant barriers such as tumor heterogeneity, immune evasion, and logistical challenges remain. This review explores strategies for developing potent cancer vaccines, examines ongoing clinical trials, evaluates immune stimulation methods, and discusses prospects for advancing in situ cancer vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesTumor MicroenvironmentNeoplasmsHumansAnimalsAdjuvants, Immunologic

Stichwörter der Autor:innen

cancerimmunosuppressionin situ vaccinenanomedicinepersonalized medicinetumor-specific antigen

Substanzen

Cancer VaccinesAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214, United States.

ORCID-Profile: Prabhanjan Giram, Youngjae You

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Giram, P., Md Mahabubur Rahman, K., Aqel, O., & You, Y. (2025). In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment. ACS Biomaterials Science & Engineering, 11(5), 2550-2583. https://doi.org/10.1021/acsbiomaterials.5c00121

Vancouver

Giram P, Md Mahabubur Rahman K, Aqel O, You Y. In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment. ACS Biomaterials Science & Engineering. 2025;11(5):2550-2583. doi:10.1021/acsbiomaterials.5c00121

BibTeX
@article{Giram2025,
  author = {Giram, Prabhanjan and Md Mahabubur Rahman, Kazi and Aqel, Osama and You, Youngjae},
  title = {In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment},
  journal = {ACS Biomaterials Science & Engineering},
  year = {2025},
  volume = {11},
  number = {5},
  pages = {2550--2583},
  doi = {10.1021/acsbiomaterials.5c00121}
}
Kostenlos starten →